Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KX2-391 Ointment in Actinic Keratosis
NCT02337205Phase 1Completed
- Sponsor
- Athenex
- Start
- Dec 2014
- Primary completion
- Mar 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of tirbanibulin in actinic keratosis (AK), sponsored by Athenex. Primary endpoints: Overall safety and tolerability assessment at 45 days and Pharmacokinetic analysis of KX2-391 at 7 days. Started Dec 2014; status: completed.
02
Drugs
tirbanibulin
03
Conditions
actinic keratosis (AK)
Beyond the preview
Go deeper on NCT02337205.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02337205.